Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））
CR059101
Phase 1 small_molecule active
Quick answer
Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059）） for T2DM is a Phase 1 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- T2DM
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active